Gastroesophageal Reflux Disease Market Size

Gastroesophageal Reflux Disease (GERD) Market Analysis

The gastroesophageal reflux disease market is poised to grow at a CAGR of 4.3% over the forecast period.

The COVID-19 pandemic impacted the market owing to supply chain disruptions due to lockdown restrictions in its initial phases. Also, the eating habits of people worldwide were affected due to the lockdown and isolation and people had started overeating which has resulted in high cases of gastroesophageal reflux diseases (GERD). Also, research studies indicated that COVID-19 severely impacted people with GERD. For instance, an article published in Human Molecular Genetics Journal in February 2022 stated that symptoms related to GERD were observed to be linked with a high risk for COVID-19. Therefore, the COVID-19 has led to an increase in demand for GERD medications during pandemic. Hence, the market witnessed a significant growth during the pandemic period.

Factors such as the rising prevalence of gastrointestinal reflux diseases, changing lifestyles, and increasing awareness about GERD are expected to fuel the market growth during the analysis period.

According to an article updated in July 2022 by the National Library of Medicine, GERD is one of the most prevalent chronic gastrointestinal disorders which affects about 20% of individuals in western culture and is defined by the regurgitation of gastric contents into the esophagus. Thus, this common condition among the target population is expected to increase awareness about the disease leading to diagnosis and treatment for the same. Thereby, it is expected to drive market growth over the forecast period.

Additionally, according to an article updated by the National Center for Biotechnology Information (NCBI) in May 2022, tobacco smoking is considered an etiological factor of reflux esophagitis or acid reflux and it is considered a major risk factor for acid reflux over the age of 50. Also, as per the article published in November 2021 by NCBI, the recent epidemiological studies stated that there is increasing GERD prevalence worldwide and the estimated prevalence of GERD ranged from 15% to 25%, while Saudi Arabia had GERD prevalence between 15% - 45.4%, Western Asia with 10%-20%, the Middle East with 8.7%-33.1%, and Eastern Asia reported less than 10% prevalence during the study. The high prevalence of the tobacco smoking and GERD is projected to boost the demand for the availability of drugs and diagnoses for the target population which is further predicted to contribute to market growth.

Furthermore, the development activities by the market players in the form of product launches, mergers, acquisitions, and investments are also expected to enhance the market growth. For instance, in October 2021, Medical City Frisco opened a new heartburn and reflux center making it the only one of its kind in Collin and Dallas counties. The Heartburn & Reflux Center offers minimally invasive robotic and laparoscopic treatment options for gastroesophageal reflux disease (GERD) and oesophageal disorders including transoral incisionless fundoplication (TIF). Such advancements are expected to drive the market to grow in the future.

Therefore, owing to the above-mentioned factors the market studied is expected to grow over the forecast period. However, the expiration of patents for blockbuster drugs and frequent product recalls are the factors are anticipated to restrain the market growth over the forecast period.